Quality of life among treatment seeking methamphetamine-dependent individuals

American Journal on Addictions

Volumn 20, Issue 4, 2011, Pages 366-372

  Gonzales, Rachel ^a,d   Ang, Alfonso ^b   Glik, Deborah C ^c   Rawson, Richard A ^a   Lee, Stella ^a   Iguchi, Martin Y ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHAMPHETAMINE;

ADULT; ARTICLE; COMORBIDITY; CONFLICT; DISEASE SEVERITY; DRUG DEPENDENCE; EDUCATIONAL STATUS; EMPLOYMENT STATUS; ETHNICITY; FEMALE; GENDER; HEALTH STATUS; HELP SEEKING BEHAVIOR; HOSPITAL ADMISSION; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; PSYCHOSOCIAL DISORDER; PSYCHOTRAUMA; QUALITY OF LIFE; SHORT FORM 36; SUICIDE;

ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; MALE; METHAMPHETAMINE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SOCIAL SUPPORT; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE TREATMENT CENTERS; TREATMENT OUTCOME;

EID: 79959373886     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2011.00142.x     Document Type: Article

References (49)

1. McLellan AT, Lewis DC, O'Brien CP, et al,. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000; 284: 1689-1695.
2. McLellan AT, Luborsky L, Woody GE, et al,. An improved diagnostic evaluation instrument for substance abuse patients, the Addiction Severity Index. J Nerv Ment Dis. 1980; 168: 26-33. (Pubitemid 10187569)
3. Fletcher BW, Tims FM, Brown BS,. The drug abuse treatment outcomes study (DATOS): Treatment evaluation research in the United States. Psychol Addict Behav. 1997; 11: 216-229. (Pubitemid 28046586)
4. Mendlowicz MV, Stein MB,. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000; 157: 669-682. (Pubitemid 30249642)
5. World Health Organization Quality of Life assessment. Position paper from the World Health Organization. Soc Sci Med. 1995; 41: 1403-1409.
6. Anglin MD, Hser YI,. Drug abuse treatment. In:, Watson RR, ed. Drug and Alcohol Abuse Reviews, Vol. 4. Totowa, NJ: Humana Press; 1992: 1-36.
7. Anglin MD, Hser YI,. Treatment of drug abuse. In:, Tonry M, Wilson JQ, eds. Drugs & Crime. Chicago: The University of Chicago Press; 1990: 393-460.
8. Evans E, Longshore D,. Evaluation of the substance abuse and crime prevention act: Treatment clients and program types during the first year of implementation. J Psychoactive Drugs. 2004; S2: 165-174. (Pubitemid 38856442)
9. Aday LA,. Health status of vulnerable populations. Annu Rev Public Health. 1994; 15: 487-509. (Pubitemid 24179013)
10. Maxwell JC, Rutkowski BA,. The prevalence of methamphetamine and amphetamine abuse in North America: A review of the indicators, 1992-2007. Drug Alcohol Rev. 2008; 27: 229-235.
11. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) Highlights-2007 National Admissions to Substance Abuse Treatment Services. OAS Series #S-45, HHS Publication No. (SMA) 09-4360. Rockville, MD: US Department of Health and Human Services; 2009.
12. Kaye S, McKetin R, Duflou J, et al,. Methamphetamine and cardiovascular pathology: A review of the evidence. Addiction. 2007; 102: 1204-1211. (Pubitemid 47039146)
13. Rawson RA, Gonzales RG, Ling W,. Methamphetamine abuse and dependence: An update. Dir Psychiatr. 2006; 26: 221-236.
14. Jaffe JA, Ling W, Rawson RA,. Amphetamines. In:, Sadock BJ, Sadock VA, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. Baltimore, MD: Lippincott; 2004; 458-484.
15. Glasner-Edwards S, Marinelli-Casey P, Gonzales R, et al,. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009; 197: 225-231.
16. Hendrickson R, Cloutier R, McConnell K,. Methamphetamine-related emergency department utilization and cost. Acad Emerg Med. 2008; 15: 23-31.
17. Brecht ML, O'Brien A, von Mayrhauser C, et al,. Methamphetamine use behaviors and gender differences. Addict Behav. 2004; 29: 89-106. (Pubitemid 37518229)
18. Herrell JM, Taylor JA, Gallagher C, et al,. A multisite study of the effectiveness of methamphetamine treatment: An initiative of the center for substance abuse treatment. J Psychoactive Drugs. 2000; 32: 143-147.
19. Huber A, Lord RH, Gulati V, et al,. The CSAT methamphetamine treatment project: Research design accommodations for "real world" application. J Psychoactive Drugs. 2000; 32 (2): 149-156.
20. Ware JE., SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, New England Medical Center; 1994.
21. McLellan AT, Kushner H, Metzger D, et al,. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992; 9: 199-213.
22. Ware JE, Snow KK, Kolinski M, et al,. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Centre; 1993.
23. McKay JR, Weiss RV,. A review of temporal effects and outcome predictors in substance abuse treatment studies with long-term follow-ups: Preliminary results and methodological issues. Eval Rev. 2001; 25: 113.
24. Predergast ML, Podus D, Chang E,. Program factors and treatment outcomes in drug dependence treatment: An examination using meta-analysis. Subst Use Misuse. 2000; 35: 1931-1965. (Pubitemid 32004733)
25. Ware JE, Gandek B, IQOLA Project Group. The SF-36 health survey: Development and use in mental health research and the IQOLA project. Int J Ment Health. 1994; 23: 49-73.
26. Millson PE, Challacombe L, Villeneuve PJ, et al,. Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Eur Addict Res. 2006; 12: 74-82.
27. Stein MD, O'Sullivan PS, Ellis P, et al,. Utilization of medical services by drug abusers in detoxification. J Subst Abuse. 1993; 5: 187-193.
28. House JS, Lepkowski JM, Kinney AM, et al,. The social stratification of aging and health. J Health Soc Behav. 1994; 35: 213-234.
29. Ryan CF, White JM,. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction. 1996; 91: 39-45. (Pubitemid 26026809)
30. Garg N, Yates WR, Jones R, et al,. Effect of gender, treatment site and psychiatric comorbidity on quality of life outcome in substance dependence. Am J Addict. 1999; 8: 44-54. (Pubitemid 29124819)
31. De Alba I, Samet JH, Saitz R,. Burden of medical illness in drug- and alcohol-dependent persons without primary care. Am J Addict. 2004; 13: 33-45. (Pubitemid 38294862)
32. Grella CE, Joshi V,. Gender differences in drug treatment careers among clients in the national drug abuse treatment outcome study. Am J Drug Alcohol Abuse. 1999; 25: 385-406. (Pubitemid 29395136)
33. Puigdollers E, Domingo-Salvany A, Brugal MT, et al,. Characteristics of heroin addicts entering methadone maintenance treatment: Quality of life and gender. Subst Use Misuse. 2004; 39: 1353-1368. (Pubitemid 39209701)
34. Cohen J, Dickow A, Horner K, et al,. Abuse and violence history of men and women in treatment for methamphetamine dependence. Am J Addict. 2003; 12: 377-385. (Pubitemid 37449024)
35. Neale J,. Suicidal intent in non-fatal illicit drug overdose. Addiction. 2000; 95: 85-93. (Pubitemid 30096755)
36. Klee H,. Drug misuse and suicide: Assessing the impact of HIV. AIDS Care. 1995; 7 (S2): S145-S155. (Pubitemid 26004531)
37. Recklitis CJ, Lockwood RA, Rothwell MA, et al,. Suicidal ideation and attempts in adult survivors of childhood cancer. J Clin Oncol. 2006; 24: 3852-3857. (Pubitemid 46630731)
38. Marusic A, Goodwin RD,. Suicidal and deliberate self-harm ideation among patients with physical illness: The role of coping styles. Suicide Life Threat Behav. 2006; 36: 323-328. (Pubitemid 44030747)
39. Costenbader E, Zule W, Coomes C,. The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for hepatitis C infection. Drug Alcohol Depend. 2007; 89: 251-258. (Pubitemid 46754678)
40. Domier CP, Simon SL, Rawson RA, et al,. A comparison on injecting and noninjecting methamphetamine users. J Psychoactive Drugs. 2000; 32: 229-232.
41. Neale J,. Measuring the health of Scottish drug users. Health Soc Care Commun. 2004; 12: 202-211. (Pubitemid 38888557)
42. Daeppen JB, Krieg MA, Burnand B, et al,. MOS-SF-36 in evaluating health-related quality of life in alcohol-dependent patients. Am J Alcohol Drug Abuse. 1998; 24: 685-694. (Pubitemid 28531739)
43. Wells KB, Stewart A, Hayes RD, et al,. The functioning and well being of depressed patients: Results from the medical outcomes study. JAMA. 1989; 262: 914-919. (Pubitemid 19208948)
44. Booth BM, Blow FC, Cook L,. Persistence of impaired functioning and psychological distress after hospitalization for men with co-occurring psychiatric and substance use disorders. J Gen Intern Med. 2001; 16: 57-65. (Pubitemid 32128697)
45. Griffin KW, Rabkin JG, Remein RH, et al,. Disease severity, physical limitations, and depression in HIV-infected men. J Psychosom Res. 1998; 44: 219-227. (Pubitemid 28056885)
46. Meredith CW, Jaffe C, Ang-Lee K, et al,. Implications of chronic methamphetamine use: A literature review. Harv Rev Psychiat. 2005; 13: 141-154. (Pubitemid 40967247)
47. O'Toole TP, Pollini RA, Ford D, et al,. Physical health as a motivator for substance abuse treatment among medically ill adults: Is it enough to keep them in treatment J Subst Abuse Treat. 2006; 31: 143-150. (Pubitemid 44226501)
48. Farabee D, Prendergast M, Cartier L,. Methamphetamine use and HIV risk among substance-abusing offenders in California. J Psychoactive Drugs. 2002; 34: 295-300. (Pubitemid 35204599)
49. Iguchi MY, London JA, Forge NG, et al,. Elements of well-being affected by criminalizing the drug user. Public Health Rep. 2002; 117 (S1): S146-S150. (Pubitemid 35351228)